Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Last trade$55.94
Day change-$0.43 (-0.76%)
Day range$54.82 – $57.11
Volume930,721
Market cap$5.08B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.08B
Price / earnings
—
Price / book
-199.71×
Price / sales
8.17×
EV / sales
7.79×
EV / EBITDA
16.44×
Profitability
Earnings per share
-$1.05
Return on assets
-13.79%
Return on equity
370.33%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-6.37×
Current ratio
1.02×
Quick ratio
0.96×
Cash ratio
0.68×
Cash flow
Price / cash flow
15.67×
Price / free cash flow
17.45×
Free cash flow
$291.15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LQDA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$225.3M
$171.68M
$132.87M
$92.02M
$54.34M
$8.84M
$3.12M
$2.92M
Cost of revenue
$14.78M
$11.55M
$11.85M
$7.06M
$3.17M
$1.5M
$1.52M
$1.35M
Gross profit
$210.52M
$160.13M
$121.01M
$84.97M
$51.17M
$7.34M
$1.6M
$1.56M
Selling, general and administrative
$59.02M
$57.43M
$46.94M
$48.24M
$40.06M
$38.82M
$30.06M
$21.2M
Research and development
$25.27M
$17.18M
$12.57M
$16.94M
$9.35M
$6.02M
$6.97M
$16.48M
Total operating expenses
$474.04M
$74.61M
$59.51M
$65.18M
$49.4M
$44.85M
$37.03M
$37.67M
Operating income
-$263.52M
$85.52M
$61.5M
$19.79M
$1.77M
-$37.51M
-$35.43M
-$36.11M
Interest expense
-$2.88M
-$6.3M
-$6.49M
-$6.9M
-$5.3M
-$5.66M
-$4.67M
-$4.51M
Income before taxes
-$266.4M
$81.7M
$56.78M
$14.56M
-$3.53M
-$41.58M
-$38.37M
-$38.51M
Income taxes
-$30.07M
$6.98M
$3.92M
$0
$0
$0
$0
$0
Net income
-$236.33M
$74.72M
$52.86M
$14.56M
-$3.53M
-$41.58M
-$38.37M
-$38.51M
Net income attributable to common shareholders
-$236.33M
$74.72M
$52.86M
$14.56M
-$3.53M
-$41.58M
-$38.37M
-$38.51M
EBITDA
$126.78M
$85.92M
$62M
$20.11M
$2.24M
-$37.22M
-$34.97M
-$35.59M
Basic earnings per share
-$2.64
$0.84
$0.60
$0.17
-$0.04
-$0.49
-$0.45
-$0.45
Diluted earnings per share
-$2.64
$0.74
$0.52
$0.17
-$0.04
-$0.49
-$0.45
-$0.45
Recent news
Company coverage with links to the original publishers.
Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.
Liquidia Corporation (LQDA) reported Q3 2026 revenues of $225.3M, surging 314.6% year-over-year, with YUTREPIA sales reaching $222.7M, up 31% sequentially. The company achieved record October patient shipments and expanded its prescriber base to 1,300 despite temporary referral disruptions following a settlement with United Therapeutics. Management maintained a 94% gross margin and plans to provide 2027 revenue guidance in January.
Liquidia Corporation (LQDA) reported Q3 2026 earnings of $0.80 per share, beating consensus estimates of $0.77, with revenues of $225.3 million exceeding expectations by 20.72%. Despite the strong earnings beat and 38.8% year-to-date stock gain, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The stock is expected to underperform the market in the near term.
Zymeworks Inc. reported Q3 2026 earnings of $2.28 per share, missing the consensus estimate of $2.40 per share by 5%, though revenues of $256.46 million exceeded expectations by 2.72%. The company has failed to surpass consensus EPS estimates over the last four quarters. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market. The Medical - Biomedical and Genetics industry ranks in the top 43% of Zacks industries.
Protagonist Therapeutics reported Q3 2026 earnings of $3.07 per share, beating consensus estimates of $2.58 per share, with a significant turnaround from a $0.62 loss per share a year ago. Revenues reached $274.41 million, surpassing estimates by 2.77% and up dramatically from $4.71 million year-over-year. The company received a Zacks Rank #2 (Buy) rating with stock up 64.2% year-to-date versus S&P 500's 12.3% gain.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.